ArticleCancer & metabolism2026
IL-6-driven metabolic reprogramming of the multiple myeloma microenvironment.
Article in Cancer & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma is an aggressive plasma cell malignancy that remains incurable despite major therapeutic advances and depends on extensive metabolic remodeling to support malignant growth and drug resistance. Although tumor cell-intrinsic mechanisms of drug resistance are well characterized, the contribution of cells in the tumor microenvironment, particularly bone marrow stromal cells, to metabolic remodeling and therapeutic resistance remains poorly understood.
methodsWe combined [U-
resultsBone marrow stromal cell co-culture induced a convergent metabolic rewiring in multiple myeloma cells, enhancing pathways previously linked to bortezomib resistance, including glycolysis, tricarboxylic acid cycle activity, serine synthesis and nucleotide biosynthesis. In parallel, stromal cells acquired a cancer-associated fibroblast-like phenotype characterized by increased interleukin-6 and transforming growth factor-β production. This cytokine milieu promoted bortezomib resistance and stromal cell activation. Interleukin-6 alone was sufficient to rescue multiple myeloma cells from bortezomib-induced cytotoxicity and reproduced a substantial fraction of the co-culture-induced metabolic remodeling. Analysis of patient proteomics revealed a strong positive association between interleukin-6 abundance and expression of enzymes involved in mitochondrial metabolism, glycolysis, serine metabolism, nucleotide metabolism and redox homeostasis.
conclusionsThese findings identify bone marrow stromal cell-derived interleukin-6 as a central driver of tumor microenvironment-mediated metabolic reprogramming and bortezomib resistance in multiple myeloma. Targeting interleukin-6-dependent metabolic signaling may represent a promising strategy to overcome stromal-driven therapeutic resistance. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.